CASI - CASI Pharmaceuticals Inc
Previous close
6.54
0 0%
Share volume: 3,853
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.54
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
| Report Date | 2022-05-12 | 2022-08-12 | 2022-11-14 | 2023-04-26 | |
| Total revenue | 9.062 M | 8.573 M | 10.213 M | 15.259 M | |
| Cost of revenue | 1.977 M | 1.865 M | 4.247 M | 7.738 M | |
| Gross profit | 7.085 M | 6.708 M | 5.966 M | 7.521 M | |
| -5.32% | -11.06% | 26.06% | |||
| Operating expenses | 12.594 M | 12.769 M | 12.320 M | 16.088 M | |
| Selling general and admin | 8.602 M | 8.918 M | 8.415 M | 11.840 M | |
| Research and development | 3.992 M | 3.851 M | 3.905 M | 4.248 M | |
| Total expenses | 14.571 M | 16.319 M | 16.567 M | 20.360 M | |
| 12.00% | 1.52% | 22.89% | |||
| Operating income | -5.509 M | -7.746 M | -6.354 M | -5.101 M | |
| Ebit | -5.509 M | -7.746 M | -6.354 M | -5.947 M | |
| Pretax income | -8.400 M | -7.493 M | -5.023 M | -17.361 M | |
| -10.80% | -32.96% | 245.63% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 1.980 M | |
| Net income basic | -8.596 M | -7.680 M | -5.201 M | -19.537 M | |
| 10.66% | 32.28% | -275.64% | |||
| Net income | -8.596 M | -7.680 M | -5.201 M | -19.537 M | |
| 10.66% | 32.28% | -275.64% |